Document is current
Any future updates will be listed below
-
Authors
Yin, Kevin
Landera, Alexander
Lee, Namil https://orcid.org/0009-0000-0382-8741
Iavarone, Anthony T.
Kosina, Suzanne M. https://orcid.org/0000-0003-2885-1248
Young, Thomas D.
Deng, Kai https://orcid.org/0000-0003-2937-8931
Baerwald, Justin
Chen, Yan https://orcid.org/0000-0002-1125-313X
Gin, Jennifer W.
Benedict, Riley
Chiu, Yan
Ukabiala, Ezechinyere
Kamruzzaman, Methun https://orcid.org/0000-0002-8680-7061
Poorey, Kunal
Northen, Trent R. https://orcid.org/0000-0001-5903-1870
Petzold, Christopher J. https://orcid.org/0000-0002-8270-5228
George, Anthe
Cruz-Morales, Pablo https://orcid.org/0000-0002-6751-8897
Dan, Qingyun https://orcid.org/0000-0002-3110-9450
Keasling, Jay D. https://orcid.org/0000-0003-4170-6088
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF24SA0100980)
Novo Nordisk Fonden (NNF20CC0035580)
Novo Nordisk Fonden (NNF24SA0100980)
U.S. Department of Energy (DEAC02-05CH11231)
DOE | Laboratory Directed Research and Development (DE-NA0003525)
DOE | Laboratory Directed Research and Development (DE-NA0003525)
DOE | Laboratory Directed Research and Development (DE-NA0003525)
DOE | Laboratory Directed Research and Development (DE-NA0003525)
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 30 April 2026
First Online: 27 May 2026
Competing interests
: J.D.K. has financial interests in Ansa Biotechnologies, Apertor Pharma, Berkeley Yeast, BioMia, Cyklos Materials, Demetrix, Lygos, Napigen, ResVita Bio, and Zero Acre Farms. The other authors declare no competing interests.
